BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30358104)

  • 1. Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer.
    Kitagawa T; Taniuchi K; Tsuboi M; Sakaguchi M; Kohsaki T; Okabayashi T; Saibara T
    Mol Oncol; 2019 Feb; 13(2):212-227. PubMed ID: 30358104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
    Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
    EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer.
    Wang WS; Liu LX; Li GP; Chen Y; Li CY; Jin DY; Wang XL
    Cancer Prev Res (Phila); 2013 Apr; 6(4):331-8. PubMed ID: 23430754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker.
    Goto T; Fujiya M; Konishi H; Sasajima J; Fujibayashi S; Hayashi A; Utsumi T; Sato H; Iwama T; Ijiri M; Sakatani A; Tanaka K; Nomura Y; Ueno N; Kashima S; Moriichi K; Mizukami Y; Kohgo Y; Okumura T
    BMC Cancer; 2018 Jan; 18(1):116. PubMed ID: 29385987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
    Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
    JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
    Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
    J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomal long noncoding RNA lnc-GNAQ-6:1 may serve as a diagnostic marker for gastric cancer.
    Li S; Zhang M; Zhang H; Hu K; Cai C; Wang J; Shi L; Ma P; Xu Y; Zheng P
    Clin Chim Acta; 2020 Feb; 501():252-257. PubMed ID: 31730812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis.
    Deng T; Yuan Y; Zhang C; Zhang C; Yao W; Wang C; Liu R; Ba Y
    Cell Physiol Biochem; 2016; 39(5):1716-1722. PubMed ID: 27639768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer.
    Xiao D; Dong Z; Zhen L; Xia G; Huang X; Wang T; Guo H; Yang B; Xu C; Wu W; Zhao X; Xu H
    Mol Cancer Res; 2020 Feb; 18(2):300-310. PubMed ID: 31662449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.
    Ritchie SA; Chitou B; Zheng Q; Jayasinghe D; Jin W; Mochizuki A; Goodenowe DB
    World J Gastroenterol; 2015 Jun; 21(21):6604-12. PubMed ID: 26074698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
    Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
    Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
    Luo G; Fan Z; Cheng H; Jin K; Guo M; Lu Y; Yang C; Fan K; Huang Q; Long J; Liu L; Xu J; Lu R; Ni Q; Warshaw AL; Liu C; Yu X
    Pancreatology; 2018 Dec; 18(8):971-976. PubMed ID: 30131287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer.
    Ren S; Wang F; Shen J; Sun Y; Xu W; Lu J; Wei M; Xu C; Wu C; Zhang Z; Gao X; Liu Z; Hou J; Huang J; Sun Y
    Eur J Cancer; 2013 Sep; 49(13):2949-59. PubMed ID: 23726266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR‑1246 and miR‑4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer.
    Machida T; Tomofuji T; Maruyama T; Yoneda T; Ekuni D; Azuma T; Miyai H; Mizuno H; Kato H; Tsutsumi K; Uchida D; Takaki A; Okada H; Morita M
    Oncol Rep; 2016 Oct; 36(4):2375-81. PubMed ID: 27573701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
    Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
    Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
    Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
    Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer.
    Usón Junior PLS; Callegaro-Filho D; Bugano DDG; Moura F; Maluf FC
    J Gastrointest Cancer; 2018 Dec; 49(4):481-486. PubMed ID: 28924968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.